Successful surgical management of multiple hepatocellular adenomas in a young female patient with glycogen storage disease type Ia: a case report Authors: Lin Ye, Renjian Li, Hao Shi, Wanrong Yue, Yaqun Yu Published: 2026 ABSTRACT AbstractBackgroundGlycogen storage disease type Ia is a rare inherited metabolic disorder characterized by glucose-6-phosphatase deficiency. Hepatocellular adenoma development is a frequent complication in patients with this condition, with prevalence rates reaching up to 75%. The management of hepatic adenomas in these patients remains challenging due to risks of hemorrhage, malignant transformation, and surgical complications.Case Presentation We report a 22-year-old Chinese female with glycogen storage disease type Ia who presented with acute metabolic decompensation, including hypoglycemia (2.8 mmol/L), severe hyperlactatemia (20.0 mmol/L), and marked hypertriglyceridemia (31.78 mmol/L). The patient had been diagnosed with glycogen storage disease type Ia at age 5 and maintained on dietary therapy. At age 18, multiple hepatic adenomas were detected. Following intensive preoperative metabolic optimization and a comprehensive perioperative management protocol, she underwent successful indocyanine green fluorescence-guided left hepatectomy at age 22 with excellent postoperative recovery and no evidence of malignant transformation.ConclusionThis case demonstrates that hepatic adenomas in patients with glycogen storage disease type Ia can be successfully managed surgically with appropriate perioperative metabolic management. Early diagnosis, regular surveillance, and timely surgical intervention are crucial for preventing life-threatening complications in this patient population.Keywords: Glycogen storage disease type Ia, Hepatocellular adenoma, Left hepatectomy, Metabolic management, Female patient Background Glycogen storage disease type Ia (GSD-Ia), also known as von Gierke disease, is an autosomal recessive disorder characterized by glucose-6-phosphatase deficiency, affecting approximately 1 in 100,000 individuals [1]. This enzyme deficiency impairs both glycogenolysis and gluconeogenesis, leading to excessive glycogen accumulation primarily in the liver and kidneys [2]. Main complications include fasting hypoglycemia, hyperuricemia, hyperlactatemia, and hyperlipidemia, especially hypertriglyceridemia [3]. These metabolic derangements, if left untreated, can result in severe complications during infancy and childhood. With the introduction of continuous glucose therapy in 1971 and uncooked cornstarch supplementation in 1982, the prognosis for children and adults with GSD-Ia has improved dramatically [4]. However, as survival has increased, long-term hepatic complications have emerged as significant concerns. Hepatocellular adenoma formation is a common sequela of GSD-Ia, with reported prevalence rates up to 75% [5]. The incidence of hepatocellular adenomas in GSD-Ia patients is approximately 30.5%, with a mean onset age of 16.5 ± 4.4 years [6]. These adenomas carry significant risks of hemorrhage and potential malignant transformation to hepatocellular carcinoma, which has been documented in multiple case series [7, 8]. The natural history of hepatic adenomas in GSD-Ia differs significantly from sporadic adenomas. GSD-associated adenomas tend to present as multiple tumors at initial detection and are increasingly recognized as premalignant lesions [9]. One cohort study reported that hepatocellular carcinoma developed in 13.8% of GSD-Ia patients with adenomas [10]. Management includes serial imaging and surgical resection of concerning lesions to avoid risks of bleeding and malignant transformation [11]. Additionally, female patients with GSD-Ia face unique challenges. Despite a high prevalence of irregular menstruation cycles and polycystic ovaries, fertility appears not to be significantly impaired in women with GSD-Ia [12]. Successful pregnancies have been reported, although careful metabolic monitoring is required throughout gestation [13]. Additionally, female patients with GSD-Ia face unique challenges. Despite a high prevalence of irregular menstrual cycles and polycystic ovaries, fertility does not appear to be significantly impaired in women with GSD-Ia. We present a case of a 22-year-old female with GSD-Ia and multiple hepatic adenomas who underwent successful surgical management, highlighting the importance of metabolic control, surveillance, and appropriate surgical timing in this challenging patient population. Case presentation The patient was a 22-year-old Chinese female with a long-standing diagnosis of GSD-Ia. She had been diagnosed at age 5 years when she presented to another hospital with epistaxis. At that time, genetic testing confirmed GSD-Ia, and she was initiated on dietary therapy with regular raw cornstarch supplementation and routine follow-up. Her parents were healthy with no history of consanguinity. The patient's pubertal development was normal, with menarche occurring at age 16 years, followed by regular menstrual cycles thereafter (Fig. 1). Clinical Timeline: From Diagnosis to Surgical Intervention. Timeline depicting the patient's disease course from diagnosis at age 5 to surgical intervention at age 22. Key events include: (1) Initial GSD-Ia diagnosis with genetic confirmation; (2) Normal pubertal development at age 16; (3) Multiple hepatic adenomas detected at age 18; (4) Acute metabolic crisis with severe hypoglycemia (2.8 mmol/L), hyperlactatemia (20.0 mmol/L), and hypertriglyceridemia (31.78 mmol/L); (5) Successful left hepatectomy with benign pathology At age 18 years, she began experiencing upper abdominal discomfort accompanied by nausea and vomiting. Abdominal ultrasound revealed hepatomegaly and multiple hepatic adenomas. Given her young age and absence of concerning features, she was managed conservatively with regular ultrasound surveillance. However, serial imaging demonstrated progressive adenoma growth over the subsequent four years. In June 2023, the patient presented to our emergency department with acute upper abdominal discomfort and fever. Physical examination revealed an alert patient with characteristic doll-like facies and short stature, measuring 148 cm in height and weighing 49.5 kg (BMI 22.6 kg/m2). There was no evidence of jaundice. Abdominal examination demonstrated marked distension with significant hepatomegaly; the liver edge was palpable at the umbilical level on the right midclavicular line and two fingerbreadths above the umbilicus on the anterior median line. Splenomegaly was also present, with the spleen palpable 3 cm below the left costal margin. Laboratory investigations revealed significant metabolic derangements consistent with poorly controlled GSD-Ia. The patient presented with hypoglycemia (glucose 2.8 mmol/L; reference range 3.9–6.1 mmol/L), marked hyperlactatemia (lactate 20.0 mmol/L; reference range 0.5–2.2 mmol/L), hyperuricemia (uric acid 667 μmol/L; reference range 155–357 μmol/L), and severe hypertriglyceridemia (triglycerides 31.78 mmol/L; reference range 0.40–1.70 mmol/L). Total cholesterol was mildly elevated at 6.1 mmol/L. Assessment of liver function and tumor markers showed reassuring results. Alpha-fetoprotein (AFP) was normal at 2.15 ng/mL, providing no evidence of malignant transformation. Total bilirubin was 3.7 μmol/L, albumin was 40.4 g/L, and prothrombin time was 13.0 s. The Child–Pugh score was 5 points (Grade A), indicating preserved liver function despite massive hepatomegaly. There was no evidence of ascites or hepatic encephalopathy. Contrast-enhanced computed tomography (CT) revealed multiple hepatocellular adenomas distributed throughout the liver parenchyma with massive hepatomegaly (Fig. 2A-C). The adenomas appeared as well-defined lesions with heterogeneous enhancement patterns. Venous phase imaging demonstrated hypodense lesions (Fig. 2A), while arterial phase showed variable enhancement (Fig. 2B). Magnetic resonance imaging confirmed hepatomegaly with diffuse fatty liver changes and multiple nodular lesions consistent with hepatocellular adenomas. Urinary ultrasound demonstrated right renal calculus with associated hydronephrosis, a known complication of chronic hyperuricemia in GSD-Ia. Imaging Studies. (A) Venous phase demonstrating well-defined hypodense lesions. (B) Arterial phase showing heterogeneous enhancement patterns. (C) Postoperative follow-up CT showing successful left hepatectomy with residual small adenomas in the remnant liver Upon presentation, the patient required immediate metabolic stabilization. She received an intravenous bolus of 100 mL of 10% glucose solution, followed by continuous infusion of 0.45% sodium chloride and 5.0% glucose at 125 mL/hour. Antibiotic therapy was initiated for concurrent infection. The patient's symptoms resolved rapidly with metabolic stabilization. After achieving metabolic stability, she was transferred to the hepatobiliary and pancreatic surgery department. Given the progressive adenoma growth, absence of contraindications to surgery (Child–Pugh Grade A), and after thorough discussion with the patient and family, surgical resection was recommended. The decision balanced the risks of hemorrhage and potential malignant transformation against perioperative risks. A comprehensive perioperative protocol was implemented to manage metabolic complications and prevent hemorrhage. Preoperative metabolic optimization was initiated 72 h before surgery, including intensified dietary management with frequent raw cornstarch supplementation (1.5–2.0 g/kg every 4–6 h) to maintain stable blood glucose levels. Serum triglycerides were reduced from 31.78 mmol/L to 15.6 mmol/L through strict dietary control and fenofibrate therapy. Continuous intravenous glucose infusion (10% dextrose at 4–6 mg/kg/min) was commenced 12 h preoperatively to ensure euglycemia. Lactate levels were monitored every 6 h preoperatively and normalized prior to surgery. The hemostatic protocol included desmopressin (0.3 μg/kg via slow infusion) administered one hour before surgery to address the platelet dysfunction known to occur in GSD patients, along with tranexamic acid (1 g intravenously) as an antifibrinolytic agent. Fresh frozen plasma was prepared as a precautionary measure. Corticosteroids (hydrocortisone 100 mg) were administered to support perioperative stress response. Fluorescence-guided left hepatectomy was performed successfully using indocyanine green (ICG) fluorescence imaging. ICG (0.5 mg/kg) was administered intravenously 24 h before surgery to enable real-time visualization of hepatic parenchyma and tumor boundaries. This technique facilitated precise identification of adenoma margins and ensured adequate resection while preserving maximal functional liver parenchyma, which is particularly important in GSD-Ia patients with glycogen-laden, enlarged livers. The operation was completed without major intraoperative complications, with estimated blood loss of approximately 300 mL. Glucose and lactate levels were monitored hourly to maintain tight metabolic control throughout the procedure. The patient’s postoperative course was excellent, with adequate glucose control maintained throughout recovery. There were no significant bleeding complications or metabolic crises. She tolerated oral intake well, and wound healing progressed without complications. Postoperative follow-up CT demonstrated successful resection of large adenomas in the left hepatic lobe, with small residual adenomas remaining in the remnant right liver (Fig. 2C). Histopathological examination confirmed multiple hepatocellular adenomas with background hepatic steatosis and glycogen accumulation (Fig. 3A,B). Hematoxylin and eosin staining showed adenomas with glycogen-laden hepatocytes (Fig. 3A), while periodic acid-Schiff staining demonstrated abundant glycogen deposition within hepatocytes, appearing as intense magenta staining (Fig. 3B). Importantly, detailed microscopic examination revealed no evidence of malignant transformation in any of the examined adenomas. Histopathological Findings of Hepatocellular Adenomas. (A) Hematoxylin and eosin (H&E) staining showing hepatocellular adenoma with glycogen-laden hepatocytes and background steatosis (original magnification × 40). (B) Periodic acid-Schiff (PAS) staining demonstrating abundant glycogen deposition (magenta staining) within hepatocytes, confirming GSD-Ia-associated hepatocellular adenoma (× 40) Discussion This case illustrates several important aspects of managing hepatic adenomas in GSD-Ia patients, particularly in young females with preserved liver function. The patient’s clinical course provides valuable insights into the natural history, surveillance strategies, and treatment considerations for this challenging complication. Our patient developed adenomas at age 18, consistent with the reported mean onset age of 16.5 ± 4.4 years[6]. Hepatic adenomas in GSD patients typically develop during puberty and increase in size or number with age[9]. The relationship between metabolic control and adenoma development has been well established. Studies using serum triglyceride concentration as a surrogate marker have shown significant correlations with adenoma progression[14, 15]. Our patient presented with markedly elevated triglycerides (31.78 mmol/L), suggesting suboptimal metabolic control despite dietary therapy. Recent studies have specifically highlighted that high childhood serum triglyceride concentrations associate with hepatocellular adenoma development in GSD-Ia patients [16], underscoring the need for aggressive metabolic optimization from an early age. Malignant transformation remains a major concern in GSD-Ia patients with hepatic adenomas. While the overall rate of malignant transformation in hepatocellular adenomas is estimated at 4–8% [17], the risk appears higher in GSD-Ia patients. One cohort study reported that hepatocellular carcinoma developed in 13.8% of GSD-Ia patients with adenomas [10]. Risk factors include male sex, adenoma size greater than 5 cm, β-catenin activation, elevated AFP, and GSD type I. Our patient's normal AFP (2.15 ng/mL) and absence of malignancy on pathological examination were reassuring, though the progressive growth pattern justified surgical intervention. The decision for surgical resection was based on several factors: progressive adenoma growth, the patient's young age, preserved liver function (Child–Pugh A), and known risks of hemorrhage and malignant transformation. Current guidelines recommend resection for hepatocellular adenomas greater than 5 cm in women [18]. Although partial hepatectomy is feasible in GSD-Ia patients, it carries substantial morbidity, with reported complication rates of 86% versus 20% in the general population [19]. The higher morbidity relates to metabolic derangements, platelet dysfunction, and technical difficulties of operating on massively enlarged, glycogen-laden livers. Perioperative hemostatic management is crucial due to platelet dysfunction in GSD patients. This dysfunction has been attributed to excess glycogen in platelets, chronic hypoglycemia, and possible circulating inhibitors [14]. Our comprehensive protocol included intensive preoperative metabolic optimization over 72 h, continuous glucose infusion, desmopressin administration, and tranexamic acid as an antifibrinolytic agent. Desmopressin increases von Willebrand factor and factor VIII levels, compensating for platelet dysfunction. Notably, we employed ICG fluorescence-guided hepatectomy, which represents a novel approach in GSD-Ia patients with hepatocellular adenomas. The fluorescence imaging technique enabled precise delineation of tumor margins and identification of satellite lesions, which is particularly valuable given the multiple adenomas and diffusely enlarged, glycogen-laden liver characteristic of this condition. This approach minimized unnecessary parenchymal resection while ensuring complete removal of target lesions, contributing to the excellent surgical outcome observed in our patient. This case highlights important considerations for female GSD-Ia patients. Our patient had normal pubertal development with menarche at age 16 and regular menstrual cycles thereafter. Despite the high prevalence of irregular menstruation and polycystic ovaries in GSD-Ia patients, fertility is generally preserved [12]. Successful pregnancies have been documented, although they require specialized management due to increased carbohydrate requirements and potential complications [13]. Case reports have documented development and enlargement of hepatic adenomas during pregnancy, potentially related to the high estrogen state [12]. By addressing the adenomas surgically before potential future pregnancies, we may have reduced risks associated with hormonal stimulation during gestation. The patient was counseled regarding the importance of optimizing metabolic control before any future pregnancy and the need for specialized prenatal care. Continued surveillance of the remnant liver is essential, as adenoma recurrence and new lesion development are common in GSD-Ia patients after surgical excision [19]. Current guidelines recommend CT or MRI at 6–12 month intervals for at least 2 years, followed by annual imaging [18]. For our patient with residual adenomas, we established a structured long-term surveillance protocol: contrast-enhanced MRI every 6 months for the first 2 years, then annually thereafter if stable; serum AFP measurements every 3 months; quarterly metabolic monitoring including fasting glucose, lactate, triglycerides, and uric acid levels; and annual assessment of liver function and renal status. Any adenoma demonstrating growth exceeding 20% in diameter or suspicious imaging features will prompt consideration for intervention. Optimization of metabolic control remains critical for potentially preventing new adenoma development [20]. The patient has been counseled on strict adherence to dietary therapy with raw cornstarch supplementation to maintain metabolic stability and potentially slow residual adenoma progression. For patients unable to undergo surgical resection, alternative modalities include transarterial embolization or radiofrequency ablation [17]. Liver transplantation remains the definitive option for extensive adenomatosis, evidence of malignant transformation, or refractory metabolic derangements. Transplantation offers the advantage of curing both hepatic complications and the underlying metabolic defect. The patient was specifically counseled regarding reproductive health considerations, including the importance of optimizing metabolic control before any future pregnancy, the need for specialized prenatal care should she become pregnant, and the potential risks related to her hepatic condition during gestation. She expressed relief at having addressed the adenomas surgically and understood the need for ongoing vigilance with regular follow-up examinations. Conclusion This case demonstrates that hepatic adenomas in GSD-Ia patients can be successfully managed surgically when appropriate patient selection and comprehensive perioperative metabolic management protocols are employed. Our experience highlights the value of ICG fluorescence-guided hepatectomy for precise tumor delineation in these challenging cases with enlarged, glycogen-laden livers. Key factors contributing to successful outcomes include early diagnosis through vigilant surveillance, intensive preoperative metabolic optimization, timely surgical intervention for progressive adenomas, comprehensive perioperative management addressing metabolic derangements and platelet dysfunction, application of advanced surgical techniques such as fluorescence guidance, and commitment to structured long-term follow-up for detection of recurrence or new lesions. For young female patients with GSD-Ia, surgical management of hepatic adenomas before potential future pregnancies may offer additional benefits by reducing risks associated with hormonal stimulation during gestation. Continued research into adenoma pathophysiology, improved metabolic management strategies, and refinement of surgical techniques will further improve outcomes for this challenging patient population. Acknowledgements We thank the patient and her family for their cooperation and consent. We acknowledge the nursing staff and allied health professionals who contributed to the care of this patient. Abbreviations Alpha-fetoprotein Body mass index Computed tomography Indocyanine green Glycogen storage disease type Ia Hematoxylin and eosin Hepatocellular carcinoma Magnetic resonance imaging Periodic acid-Schiff Author contributions L.Y.was the principal designer of the work and the leader of the research team and conceived of the study. R.J.L. and H.S.participated in data curation. W.R.Y. was responsible for pathological examination. Y.Q.Y was responsible for patient management and overall coordination. All authors reviewed and approved the final version of the manuscript. Funding This work was funded by Guilin Scientific Research and Technology Development Plan Project [2024] No. 17 [grant number 20230135–1-3], the Guangxi Medical and Health Key Discipline Construction Project 2021 and The Innovation Project of Guangxi Graduate Education (YCBZ2025197). Availability of data and materials Further data is available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate Ethical approval was not required for this single case report, in accordance with the policy of the Ethics Committee of the First Affiliated Hospital of Guilin Medical University. Written informed consent was obtained from the patient for publication of this case report and any accompanying images. Consent for publication Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. Competing interests The authors declare that they have no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Lin Ye and Renjian Li contributed equally to this work. References Associated Data Data Availability Statement Further data is available from the corresponding author upon reasonable request.